LFLouis Foucault

Louis Foucault

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Louis Foucault has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Selective vulnerability of intracortical projection neurons drives long-term cortical circuit rewiring after perinatal hypoxia

    by Salma Ellouze, Elodie Babina, Géraldine Meyer-Dilhet, Louis Foucault, Amel Amara, Stevenson Desmercière, Thomas Gagnieu, Sandrine Mongellaz, Anis Cataldi, Guillaume Marcy, et al.

    Cortical circuits are built at perinatal times and gradually refined in an activity-dependent manner during a so-called postnatal period of critical plasticity. Although lesions of the central nervous system (CNS) happening during this period typically recover better than those occurring later in life, they are often associated with long-term behavioral deficits. This suggests that neuronal circuits rewiring, in particular within the cortex, may either be incomplete or inappropriate. To address this possibility, we used chronic perinatal hypoxia, a mouse model of very premature birth. We confirmed that chronic hypoxia induced a decrease in cortical thickness frequently observed in very preterm babies, which rapidly recovered 8 days later. To explore the transcriptional correlates of this recovery we next performed singlenuclei transcriptomic analysis of the cortex at short (P11) and long (P45) timepoints following hypoxia. This revealed persistent transcriptional changes within neurons, including of genes involved in mitochondrial metabolism, axonogenesis and synaptogenesis. Further, histological analysis using anterograde and retrograde tracing as well as mitochondrial labelling support persistent alterations in upper cortical neurons resulting in increased corticocortical connectivity within the cortex of adult hypoxic mice. Finally, behavioral testing revealed altered social behavior in mice exposed to chronic hypoxia, which amplified with age. Altogether, our results unravel how brain lesions happening early in life, alter normal cortical development and have long term consequences on cortical wiring, contributing to the observed behaviors defects appearing later in life.

  • Dorsal subventricular zone neural stem cells diversity, dynamics and regenerative potential

    by Louis Foucault

    Diversité, dynamiques et potentiel régénératif des cellules souches neurales de la zone sous ventriculaire dorsale: La zone sous-ventriculaire (ZSV) contient des cellules souches neurales (CSNs) dont l’activité persiste après la naissance produisant des cellules gliales et des neurones. Après la naissance, la neurogenèse devient exclusivement gabaergique, la capacité de la ZSV à produire des neurones glutamatergiques déclinant rapidement. Les mécanismes aboutissant à ce déclin et la possibilité de réactiver cette neurogenèse glutamatergique dans un contexte lésionnel, restent à évaluer. Nous avons effectué une analyse du transcriptome de cellules uniques de la ZSV dorsale postnatale afin d’explorer les mécanismes aboutissant au déclin de l’activité germinale glutamatergique. Nous décrivons une entrée en quiescence profonde des CSNs palliales, qui corrèle avec une activité de la signalisation Tgfꞵ et une expression du facteur de transcription Hopx. Cette entrée en quiescence massive est accompagnée d’une différenciation anormale des progéniteurs glutamatergiques. Ainsi, plusieurs mécanismes convergent pour clore l'activité germinale glutamatergique de la ZSV. Nous avons ensuite utilisé un modèle de lésion néonatale (hypoxie chronique) pour tester la compétence des CSNs à participer à la régénération du tissu. Une analyse histologique et transcriptomique indique une réactivation des CSNs de la ZSV dorsale, qui aboutit à la production limitée de neurones glutamatergiques corticaux dont la spécification et la maturation peuvent être encouragés par une activation pharmacologique de la voie de signalisation Wnt/ꞵ-caténine. Dans son ensemble, mon travail apporte de nouvelles connaissances sur la dynamique et la compétence des CSNs de la ZSV dorsale, dans un tissu sain ou lésé.

  • Open Access

    Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair

    by Jean-Baptiste Huré, Louis Foucault, Litsa Maria Ghayad, Corentine Marie, Nicolas Vachoud, Lucas Baudouin, Rihab Azmani, Natalija Ivjanin, Alvaro Arevalo-Nuevo, Morgane Pigache, et al.

    Oligodendrocytes are the myelin-forming cells of the central nervous system (CNS), with oligodendroglial pathologies leading to strong disabilities, from early preterm-birth brain injury (PBI) to adult multiple sclerosis (MS). No medication presenting convincing repair capacity in humans has been approved for these pathologies so far. Here, we present a pharmacogenomic approach leading to the identification of small bioactive molecules with a large pro-oligodendrogenic activity, selected through an expert curation scoring strategy ( OligoScore ) of their large impact on transcriptional programs controlling oligodendrogenesis and (re)myelination. We demonstrate the pro-oligodendrogenic activity of these compounds in vitro, using neural and oligodendrocyte progenitor cell (OPC) cultures, as well as ex vivo, using organotypic cerebellar explant cultures. Focusing on the two most promising molecules, i.e. leucovorin and dyclonine, we tested their therapeutic efficacy using a mouse model of neonatal chronic hypoxia, which faithfully mimics aspects of PBI. In this model, both compounds promoted proliferation and oligodendroglial fate acquisition from neural stem/progenitor cells, with leucovorin also promoting their differentiation. We extended these findings to an adult focal de/remyelination mouse MS model, in which both compounds improved lesion repair by promoting OPC differentiation while maintaining the pool of OPCs, and in parallel, by accelerating the transition from pro-inflammatory to pro-regenerative microglial profiles and myelin debris clearance. This study paves the way for clinical trials aimed at repurposing these FDA-approved compounds to treat myelin pathologies such as PBI and MS. Graphical Pharmacogenomic screening identifies and repurposes dyclonine and leucovorin as pro-oligodendrogenic and pro-myelinating compounds. Schematics of the pharmacogenomic approach leading to the identification of small bioactive molecules (compounds) with potential pro-oligodendrogenic activity, followed by the in vitro validation of the top compounds using neural and oligodendrocyte progenitor cell (OPC) cultures as well as organotypic cerebellar explants. The therapeutic efficacy of the top two compounds, leucovorin and dyclonine, both approved by the Food and Drug Administration (FDA), was assessed in vivo using two clinically relevant mouse models of myelin pathologies. In the neonatal hypoxia mouse model, mimicking some aspects of preterm brain injury, both leucovorin and dyclonine promoted neural stem cell (NSC) differentiation into OPCs and OPC proliferation, with leucovorin additionally restoring the density of myelinating OLs found in normoxic conditions. In an adult focal de/remyelination mouse model of multiple sclerosis, both compounds significantly improved lesion repair in adult mice by promoting OPC differentiation while preserving the pool of OPCs, and by accelerating myelin debris clearance and shifting microglia from pro-inflammatory to pro-regenerative profiles.

  • Open Access

    Single-cell analysis of the postnatal dorsal V-SVZ reveals a role for Bmpr1a signaling in silencing pallial germinal activity

    by Guillaume Marcy, Louis Foucault, Elodie Babina, Timothy Capeliez, Emeric Texeraud, Stefan Zweifel, Christophe Heinrich, Hector Hernandez-Vargas, Carlos Parras, Denis Jabaudon, et al.

    The ventricular-subventricular zone (V-SVZ) is the largest neurogenic region of the postnatal forebrain, containing neural stem cells (NSCs) that emerge from both the embryonic pallium and subpallium. Despite of this dual origin, glutamatergic neurogenesis declines rapidly after birth, while GABAergic neurogenesis persists throughout life. We performed single-cell RNA sequencing of the postnatal dorsal V-SVZ for unraveling the mechanisms leading to pallial lineage germinal activity silencing. We show that pallial NSCs enter a state of deep quiescence, characterized by high bone morphogenetic protein (BMP) signaling, reduced transcriptional activity and Hopx expression, while in contrast, subpallial NSCs remain primed for activation. Induction of deep quiescence is paralleled by a rapid blockade of glutamatergic neuron production and differentiation. Last, manipulation of Bmpr1a demonstrates its key role in mediating these effects. Together, our results highlight a central role of BMP signaling in synchronizing quiescence induction and blockade of neuronal differentiation to rapidly silence pallial germinal activity after birth.


  • Open Access

    Single cell analysis of the dorsal V-SVZ reveals differential quiescence of postnatal pallial and subpallial neural stem cells driven by TGFbeta/BMP-signalling

    by Guillaume Marcy, Louis Foucault, Elodie Babina, Emeric Texeraud, Stefan Zweifel, Christophe Heinrich, Hector Hernandez-Vargas, Carlos Parras, Denis Jabaudon, Olivier Raineteau

    The ventricular-subventricular zone (V-SVZ) is the largest neurogenic region of the postnatal forebrain, containing neural stem cells (NSCs) that emerge from both the embryonic pallium and subpallium. Despite of this dual origin, glutamatergic neurogenesis declines rapidly after birth, while gabaergic neurogenesis persists throughout life. Here, we performed single-cell RNA-sequencing (scRNA-Seq) of the postnatal dorsal V-SVZ for unravelling the mechanisms leading to pallial lineage germinal activity silencing. We identify cell lineage-specific NSCs primed for the generation of neurons or glial cells, as well as a large population of so far uncharacterized quiescent NSCs (qNSC). Pallial qNSCs enter a state of deep quiescence, characterized by persistent TGFbeta/BMP signalling, reduced transcriptional activity and Hopx expression, whilst in contrast, subpallial qNSCs remain transcriptionally primed for activation. Induction of deep pallial quiescence is paralleled by a rapid blockade of glutamatergic neuron production and differentiation. Finally, manipulation of the TGFbeta/BMP receptor Bmpr1a demonstrate its key role in mediating these effects at early postnatal times. Together, our results highlight a central role of TGFbeta/BMP-signalling in synchronizing quiescence induction and blockade of neuronal differentiation to rapidly silence pallial germinal activity after birth.